Ozempic is a diabetes medicine used with diet and exercise to treat adults whose type 2 diabetes is not satisfactorily controlled. Ozempic contains the active substance semaglutide.
According to Novo Nordisk, the marketing authorisation holder for Ozempic, production issues in August at a manufacturing site will lead to a reduction in the overall supply of the 1mg strength of Ozempic to Ireland and other EU markets during the month of September. A potential further brief (approximately one week) constraint of the 0.5mg strength is anticipated in early October.
Novo Nordisk has confirmed that these production issues are now resolved. It is expected that supply of the 1mg strength to Ireland will return to standard 2023 levels from October.
Further Information and guidance relating to this supply interruption is available for healthcare professionals and patients.